GeneDx (NASDAQ:WGS) Raised to “Hold” at Zacks Research

GeneDx (NASDAQ:WGS) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

A number of other equities research analysts have also weighed in on WGS. Canaccord Genuity Group set a $75.00 target price on shares of GeneDx and gave the stock a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. BTIG Research lowered their price objective on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Craig Hallum restated a “buy” rating and issued a $85.00 target price on shares of GeneDx in a report on Tuesday, May 5th. Finally, Guggenheim reaffirmed a “buy” rating and set a $74.00 target price (up from $70.00) on shares of GeneDx in a research report on Monday, June 29th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.43.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $63.69 on Tuesday. GeneDx has a twelve month low of $32.21 and a twelve month high of $170.87. The stock’s 50 day moving average is $59.88 and its 200-day moving average is $70.44. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -23.76 and a beta of 1.90.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. During the same period in the previous year, the business posted ($0.23) EPS. Sell-side analysts forecast that GeneDx will post -1 EPS for the current fiscal year.

Insiders Place Their Bets

In other GeneDx news, Director Keith A. Meister bought 533,758 shares of the stock in a transaction dated Thursday, May 7th. The shares were bought at an average cost of $37.86 per share, for a total transaction of $20,208,077.88. Following the purchase, the director directly owned 3,761,908 shares of the company’s stock, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Casdin Capital, Llc purchased 185,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the acquisition, the director directly owned 3,367,164 shares in the company, valued at $143,441,186.40. The trade was a 5.81% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. 25.17% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WGS. Handelsbanken Fonder AB grew its position in shares of GeneDx by 17.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 6,200 shares of the company’s stock valued at $426,000 after acquiring an additional 900 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of GeneDx by 219.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 303,433 shares of the company’s stock worth $20,831,000 after purchasing an additional 208,305 shares during the period. Bank of America Corp DE lifted its stake in GeneDx by 77.5% in the first quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock valued at $15,066,000 after purchasing an additional 102,456 shares during the last quarter. California State Teachers Retirement System lifted its stake in GeneDx by 31.2% in the first quarter. California State Teachers Retirement System now owns 25,045 shares of the company’s stock valued at $1,608,000 after purchasing an additional 5,951 shares during the last quarter. Finally, Ashford Capital Management Inc. grew its holdings in GeneDx by 31.9% during the first quarter. Ashford Capital Management Inc. now owns 174,512 shares of the company’s stock valued at $11,207,000 after purchasing an additional 42,186 shares during the period. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: GeneDx has an average analyst recommendation of “Moderate Buy,” suggesting some analysts continue to see recovery or long-term value in the company despite recent volatility. GeneDx analyst recommendation
• Negative Sentiment: Multiple law firms announced or promoted a securities class action against GeneDx and certain officers. The case covers investors who purchased shares from April 16, 2025, through May 4, 2026, with an August 3, 2026 deadline to seek lead-plaintiff status. The repeated notices increase the visibility of the legal risk and may weigh on investor confidence. GeneDx class action announcement
• Negative Sentiment: The allegations focus on claims that GeneDx concealed deteriorating reimbursement rates and margin compression. Other notices allege that the company overstated the performance and strategic benefits of its Fabric Genomics acquisition, which allegedly resulted in a $31.2 million write-off and contributed to a roughly 49% stock decline. These are allegations, not proven findings. GeneDx shareholder alert
• Negative Sentiment: The litigation headlines add to existing fundamental concerns: GeneDx’s latest reported quarter missed both revenue and EPS expectations, and analysts expect a full-year loss. Potential legal costs, settlement exposure, and additional scrutiny could further pressure the valuation. GeneDx deadline alert

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.